Eli Lilly 2013 Annual Report Download - page 2

Year in Review
1 Financial Highlights
2 Letter to Shareholders
6 Determination Leads to Discovery
12 Pipeline of Molecules in Clinical Development
Financials
2 Business
13 Risk Factors
19 Management’s Discussion and Analysis of Results of Operations
and Financial Condition
36 Consolidated Statements of Operations
37 Consolidated Statements of Comprehensive Income
38 Consolidated Balance Sheets
39 Consolidated Statements of Shareholders’ Equity
40 Consolidated Statements of Cash Flows
41 Notes to Consolidated Financial Statements
76 Management’s Reports
78
Reports of Independent Registered Public Accounting Firm
80 Selected Financial Data
For more information on Lilly’s commitment to corporate
responsibility, please see the inside back cover of this report.
Proxy Statement
1 Notice of Annual Meeting of Shareholders
2 Proxy Statement Overview
6 Board Operations and Governance
14 Director Compensation
16 Director Independence
17 Committees of the Board of Directors
19 Membership and Meetings of the Board and Its Committees
19 Board Oversight of Compliance and Risk Management
20 Highlights of the Company’s Corporate Governance
23 Compensation Discussion and Analysis
36 Compensation Committee Matters
37 Compensation Committee Interlocks and Insider Participation
38 Executive Compensation
47 Ownership of Company Stock
48 Items of Business To Be Acted Upon at the Meeting
52 Meeting and Voting Logistics
54 Other Matters
55 Appendix A
57 Annual Meeting Admission Ticket
59 Executive Committee and Senior Leadership
60 Corporate Information
DETERMINATION LEADS TO DISCOVERY
In 2013, Lilly demonstrated the determination that has been a hallmark of our company since its founding. We continued to
meet the performance goals we set for the current period of patent expirations for some of our major products, while setting the
stage to resume growth, submitting four potential medicines for regulatory approval.
ese potential treatments for diabetes and cancer reect our determination to discover new medicines that make a dierence for
people’s lives, and our unwavering resolve to make the investment necessary to sustain that work.
is is our heritage. Lilly was founded for the unique purpose of making trusted medicines of the highest possible quality, based on
the best science of the day, and for 137 years we have worked hard to honor our founders’ commitment to quality and integrity.
With the expiration of U.S. patents on Cymbalta® in December 2013 and Evista® in March 2014, we face the most challenging
year in Lilly’s history. But it is also one of the most exciting, with the prospect of launching as many as three new medicines. And
even as we focus on bringing our medicines to the people who need them, Lilly scientists continue to carry out the dicult work
of discovery that will lead to new and better therapies in the future.
From our research laboratories, to our manufacturing plants, to our relationships with payers, physicians, and the people they
serve, our determination to make life better shines through every aspect of our work. e pages that follow highlight stories of
this singular determination, as well as the progress we’ve made.
THE LILLY PROMISE
Lilly unites caring with discovery to make life better for people around the world.
Our Mission
Lilly makes medicines that help people live longer, healthier, more active lives.
Our Values
Integrity, excellence, respect for people
Our Vision
To make a signicant contribution to humanity by improving global health in the 21st century